Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 Dec 15;368(Pt 3):741–751. doi: 10.1042/BJ20020791

Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.

Chun-Nam Lok 1, Alexander J Lang 1, Shelagh E L Mirski 1, Susan P C Cole 1
PMCID: PMC1223026  PMID: 12197834

Abstract

Eukaryotic topoisomerase II (topo II) catalyses topological genomic changes essential for chromosome segregation, chromatin reorganization, DNA replication and transcription. Mammalian topo II exists as two isoforms, designated alpha and beta. Human topo IIalpha is an important cancer drug target, and an established determinant of drug sensitivity and resistance. Human topo IIbeta is also the target of anticancer drugs but its role in drug resistance is less clear. The two human topo II proteins are encoded by the TOP2A and TOP2B genes, respectively, which despite their highly conserved structural organization, are subject to distinctly different modes of regulation. In the present study, we have cloned and characterized the human TOP2B promoter containing a 1.3 kb fragment of the 5'-flanking and untranslated region (-1067 to +193). We found that the promoter activity of this TOP2B fragment was constant throughout the cell cycle, in contrast to the activity of the proximal promoter of TOP2A which was low in resting cells and enhanced during proliferation. Analyses of 5'-serially and internally deleted luciferase reporter constructs revealed that 80% of the TOP2B promoter activity could be attributed to the region between -533 and -481. Mutational analyses of putative regulatory elements indicated that two inverted CCAAT boxes (ICBs) within this region were essential for TOP2B promoter activity and gel mobility-shift assays indicated these sites bound the transcription factor nuclear factor-Y (NF-Y). Co-transfection experiments using a dominant-negative form of subunit A of NF-Y suggested that TOP2B promoter activity required direct interaction of NF-Y with the ICBs. In addition, a specificity protein-1 (Sp1)-binding GC box located just upstream of the ICBs was shown to contribute to TOP2B promoter activity in a synergistic manner with the ICBs. Our results suggest that the binding sites for NF-Y and Sp1 are critical for TOP2B transcription.

Full Text

The Full Text of this article is available as a PDF (341.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi N., Nomoto M., Kohno K., Koyama H. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene. 2000 Mar 7;245(1):49–57. doi: 10.1016/s0378-1119(00)00040-8. [DOI] [PubMed] [Google Scholar]
  2. Andrews N. C., Faller D. V. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res. 1991 May 11;19(9):2499–2499. doi: 10.1093/nar/19.9.2499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Austin C. A., Marsh K. L. Eukaryotic DNA topoisomerase II beta. Bioessays. 1998 Mar;20(3):215–226. doi: 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  4. Badie C., Itzhaki J. E., Sullivan M. J., Carpenter A. J., Porter A. C. Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells. Mol Cell Biol. 2000 Apr;20(7):2358–2366. doi: 10.1128/mcb.20.7.2358-2366.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bonfanti M., La Valle E., Fernandez Sousa Faro J. M., Faircloth G., Caretti G., Mantovani R., D'Incalci M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999 Jun;14(3):179–186. [PubMed] [Google Scholar]
  6. Capranico G., Tinelli S., Austin C. A., Fisher M. L., Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta. 1992 Aug 17;1132(1):43–48. doi: 10.1016/0167-4781(92)90050-a. [DOI] [PubMed] [Google Scholar]
  7. Champoux J. J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369–413. doi: 10.1146/annurev.biochem.70.1.369. [DOI] [PubMed] [Google Scholar]
  8. Coustry F., Hu Q., de Crombrugghe B., Maity S. N. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure. J Biol Chem. 2001 Aug 20;276(44):40621–40630. doi: 10.1074/jbc.M106918200. [DOI] [PubMed] [Google Scholar]
  9. Dorn A., Bollekens J., Staub A., Benoist C., Mathis D. A multiplicity of CCAAT box-binding proteins. Cell. 1987 Sep 11;50(6):863–872. doi: 10.1016/0092-8674(87)90513-7. [DOI] [PubMed] [Google Scholar]
  10. Drake F. H., Hofmann G. A., Bartus H. F., Mattern M. R., Crooke S. T., Mirabelli C. K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 1989 Oct 3;28(20):8154–8160. doi: 10.1021/bi00446a029. [DOI] [PubMed] [Google Scholar]
  11. Errington F., Willmore E., Tilby M. J., Li L., Li G., Li W., Baguley B. C., Austin C. A. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol. 1999 Dec;56(6):1309–1316. doi: 10.1124/mol.56.6.1309. [DOI] [PubMed] [Google Scholar]
  12. Falck J., Jensen P. B., Sehested M. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIalpha gene. J Biol Chem. 1999 Jun 25;274(26):18753–18758. doi: 10.1074/jbc.274.26.18753. [DOI] [PubMed] [Google Scholar]
  13. Faniello M. C., Bevilacqua M. A., Condorelli G., de Crombrugghe B., Maity S. N., Avvedimento V. E., Cimino F., Costanzo F. The B subunit of the CAAT-binding factor NFY binds the central segment of the Co-activator p300. J Biol Chem. 1999 Mar 19;274(12):7623–7626. doi: 10.1074/jbc.274.12.7623. [DOI] [PubMed] [Google Scholar]
  14. Farina A., Manni I., Fontemaggi G., Tiainen M., Cenciarelli C., Bellorini M., Mantovani R., Sacchi A., Piaggio G. Down-regulation of cyclin B1 gene transcription in terminally differentiated skeletal muscle cells is associated with loss of functional CCAAT-binding NF-Y complex. Oncogene. 1999 May 6;18(18):2818–2827. doi: 10.1038/sj.onc.1202472. [DOI] [PubMed] [Google Scholar]
  15. Furukawa M., Uchiumi T., Nomoto M., Takano H., Morimoto R. I., Naito S., Kuwano M., Kohno K. The role of an inverted CCAAT element in transcriptional activation of the human DNA topoisomerase IIalpha gene by heat shock. J Biol Chem. 1998 Apr 24;273(17):10550–10555. doi: 10.1074/jbc.273.17.10550. [DOI] [PubMed] [Google Scholar]
  16. Gao H., Huang K. C., Yamasaki E. F., Chan K. K., Chohan L., Snapka R. M. XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12168–12173. doi: 10.1073/pnas.96.21.12168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Grue P., Grässer A., Sehested M., Jensen P. B., Uhse A., Straub T., Ness W., Boege F. Essential mitotic functions of DNA topoisomerase IIalpha are not adopted by topoisomerase IIbeta in human H69 cells. J Biol Chem. 1998 Dec 11;273(50):33660–33666. doi: 10.1074/jbc.273.50.33660. [DOI] [PubMed] [Google Scholar]
  18. Harker W. G., Slade D. L., Drake F. H., Parr R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry. 1991 Oct 15;30(41):9953–9961. doi: 10.1021/bi00105a020. [DOI] [PubMed] [Google Scholar]
  19. Harker W. G., Slade D. L., Parr R. L., Feldhoff P. W., Sullivan D. M., Holguin M. H. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res. 1995 Apr 15;55(8):1707–1716. [PubMed] [Google Scholar]
  20. Herzog C. E., Holmes K. A., Tuschong L. M., Ganapathi R., Zwelling L. A. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha. Cancer Res. 1998 Dec 1;58(23):5298–5300. [PubMed] [Google Scholar]
  21. Hochhauser D., Stanway C. A., Harris A. L., Hickson I. D. Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene. J Biol Chem. 1992 Sep 15;267(26):18961–18965. [PubMed] [Google Scholar]
  22. Hopfner R., Mousli M., Jeltsch J. M., Voulgaris A., Lutz Y., Marin C., Bellocq J. P., Oudet P., Bronner C. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression. Cancer Res. 2000 Jan 1;60(1):121–128. [PubMed] [Google Scholar]
  23. Hu Z., Jin S., Scotto K. W. Transcriptional activation of the MDR1 gene by UV irradiation. Role of NF-Y and Sp1. J Biol Chem. 2000 Jan 28;275(4):2979–2985. doi: 10.1074/jbc.275.4.2979. [DOI] [PubMed] [Google Scholar]
  24. Isaacs R. J., Davies S. L., Sandri M. I., Redwood C., Wells N. J., Hickson I. D. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1998 Oct 1;1400(1-3):121–137. doi: 10.1016/s0167-4781(98)00131-6. [DOI] [PubMed] [Google Scholar]
  25. Isaacs R. J., Harris A. L., Hickson I. D. Regulation of the human topoisomerase IIalpha gene promoter in confluence-arrested cells. J Biol Chem. 1996 Jul 12;271(28):16741–16747. doi: 10.1074/jbc.271.28.16741. [DOI] [PubMed] [Google Scholar]
  26. Jean Didier, Guillaume Nathalie, Frade Raymond. Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. Biochem J. 2002 Jan 1;361(Pt 1):173–184. doi: 10.1042/0264-6021:3610173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Jenkins J. R., Ayton P., Jones T., Davies S. L., Simmons D. L., Harris A. L., Sheer D., Hickson I. D. Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587–5592. doi: 10.1093/nar/20.21.5587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Juenke J. M., Holden J. A. The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim Biophys Acta. 1993 Nov 16;1216(2):191–196. doi: 10.1016/0167-4781(93)90144-3. [DOI] [PubMed] [Google Scholar]
  29. Kimura K., Saijo M., Ui M., Enomoto T. Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem. 1994 Jan 14;269(2):1173–1176. [PubMed] [Google Scholar]
  30. Kurz E. U., Wilson S. E., Leader K. B., Sampey B. P., Allan W. P., Yalowich J. C., Kroll D. J. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther. 2001 Dec;1(2):121–131. [PubMed] [Google Scholar]
  31. Lang A. J., Mirski S. E., Cummings H. J., Yu Q., Gerlach J. H., Cole S. P. Structural organization of the human TOP2A and TOP2B genes. Gene. 1998 Oct 23;221(2):255–266. doi: 10.1016/s0378-1119(98)00468-5. [DOI] [PubMed] [Google Scholar]
  32. Li T. K., Liu L. F. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 2001;41:53–77. doi: 10.1146/annurev.pharmtox.41.1.53. [DOI] [PubMed] [Google Scholar]
  33. Liberati C., Ronchi A., Lievens P., Ottolenghi S., Mantovani R. NF-Y organizes the gamma-globin CCAAT boxes region. J Biol Chem. 1998 Jul 3;273(27):16880–16889. doi: 10.1074/jbc.273.27.16880. [DOI] [PubMed] [Google Scholar]
  34. Manni I., Mazzaro G., Gurtner A., Mantovani R., Haugwitz U., Krause K., Engeland K., Sacchi A., Soddu S., Piaggio G. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem. 2000 Nov 28;276(8):5570–5576. doi: 10.1074/jbc.M006052200. [DOI] [PubMed] [Google Scholar]
  35. Mantovani R. The molecular biology of the CCAAT-binding factor NF-Y. Gene. 1999 Oct 18;239(1):15–27. doi: 10.1016/s0378-1119(99)00368-6. [DOI] [PubMed] [Google Scholar]
  36. Mirski S. E., Sparks K. E., Yu Q., Lang A. J., Jain N., Campling B. G., Cole S. P. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. Int J Cancer. 2000 Feb 15;85(4):534–539. doi: 10.1002/(sici)1097-0215(20000215)85:4<534::aid-ijc15>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  37. Morgan S. E., Beck W. T. Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells. Mol Pharmacol. 2001 Feb;59(2):203–211. doi: 10.1124/mol.59.2.203. [DOI] [PubMed] [Google Scholar]
  38. Ng S. W., Liu Y., Schnipper L. E. Cloning and characterization of the 5'-flanking sequence for the human DNA topoisomerase II beta gene. Gene. 1997 Dec 12;203(2):113–119. doi: 10.1016/s0378-1119(97)00500-3. [DOI] [PubMed] [Google Scholar]
  39. Roder K., Wolf S. S., Beck K. F., Schweizer M. Cooperative binding of NF-Y and Sp1 at the DNase I-hypersensitive site, fatty acid synthase insulin-responsive element 1, located at -500 in the rat fatty acid synthase promoter. J Biol Chem. 1997 Aug 22;272(34):21616–21624. doi: 10.1074/jbc.272.34.21616. [DOI] [PubMed] [Google Scholar]
  40. Roder K., Wolf S. S., Larkin K. J., Schweizer M. Interaction between the two ubiquitously expressed transcription factors NF-Y and Sp1. Gene. 1999 Jun 24;234(1):61–69. doi: 10.1016/s0378-1119(99)00180-8. [DOI] [PubMed] [Google Scholar]
  41. Suske G. The Sp-family of transcription factors. Gene. 1999 Oct 1;238(2):291–300. doi: 10.1016/s0378-1119(99)00357-1. [DOI] [PubMed] [Google Scholar]
  42. Tan K. B., Dorman T. E., Falls K. M., Chung T. D., Mirabelli C. K., Crooke S. T., Mao J. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 1992 Jan 1;52(1):231–234. [PubMed] [Google Scholar]
  43. Tolner B., Hartley J. A., Hochhauser D. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs. Mol Pharmacol. 2001 Apr;59(4):699–706. doi: 10.1124/mol.59.4.699. [DOI] [PubMed] [Google Scholar]
  44. Tsai-Pflugfelder M., Liu L. F., Liu A. A., Tewey K. M., Whang-Peng J., Knutsen T., Huebner K., Croce C. M., Wang J. C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7177–7181. doi: 10.1073/pnas.85.19.7177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wang Q., Zambetti G. P., Suttle D. P. Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol. 1997 Jan;17(1):389–397. doi: 10.1128/mcb.17.1.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 1991 Apr;2(4):209–214. [PubMed] [Google Scholar]
  47. Wright K. L., Moore T. L., Vilen B. J., Brown A. M., Ting J. P. Major histocompatibility complex class II-associated invariant chain gene expression is up-regulated by cooperative interactions of Sp1 and NF-Y. J Biol Chem. 1995 Sep 8;270(36):20978–20986. doi: 10.1074/jbc.270.36.20978. [DOI] [PubMed] [Google Scholar]
  48. Xiao H., Hasegawa T., Isobe K. p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem. 2000 Jan 14;275(2):1371–1376. doi: 10.1074/jbc.275.2.1371. [DOI] [PubMed] [Google Scholar]
  49. Yang X., Li W., Prescott E. D., Burden S. J., Wang J. C. DNA topoisomerase IIbeta and neural development. Science. 2000 Jan 7;287(5450):131–134. doi: 10.1126/science.287.5450.131. [DOI] [PubMed] [Google Scholar]
  50. Yoon J. H., Kim J. K., Rha G. B., Oh M., Park S. H., Seong R. H., Hong S. H., Park S. D. Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter. Biochem J. 1999 Dec 1;344(Pt 2):367–374. [PMC free article] [PubMed] [Google Scholar]
  51. Yu Q., Mirski S. E., Sparks K. E., Cole S. P. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II alpha in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry. 1997 May 13;36(19):5868–5877. doi: 10.1021/bi962400y. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES